Lilly Boosts ADC Portfolio with CrossBridge Bio Deal

Eli Lilly to buy CrossBridge Bio for up to $300M (LLY:NYSE)

Eli Lilly (LLY) stock is in focus as the company agrees to acquire CrossBridge Bio, a cancer-focused biotech startup, for up to $300M in cash. Read more here.

Lilly boosts ADC portfolio with CrossBridge Bio deal

Worth up to $300 million, the buyout is Lilly’s latest of an ADC maker and adds technology for making “dual-payload” therapies.

Lilly to acquire CrossBridge Bio for up to $300m

Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.

CE-Ventures announces acquisition of portfolio company CrossBridge Bio by Eli Lilly

Innovative biotechnology company CrossBridge Bio to be acquired by US pharmaceutical major Eli Lilly in up to USD 300 million deal

CrossBridge Bio Enters an Agreement to be Acquired by ...

CrossBridge Bio Acquired by Eli Lilly and Co. for up to $300 Million // Cooley // Global Law Firm